Topics:
Radiation Oncology • Thoracic Malignancies • Medical Oncology • Immunotherapy • Non-small cell lung cancer • Stage III
Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?
Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.
Answer from: Medical Oncologist at Academic Institution
Given the heterogeneity of pneumonitis presentation, the presence of pre-checkpoint inhibitor chest/mediastinal irradiation (by definition in this trial), and the other risk factors often seen in this population (COPD/emphysema, current/past smoking history), it is a real challenge to decipher pulmo...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I’m seeing slightly higher incidence of pneumonitis in my practice than PACIFIC trial.